Immuneering Corp Cl A (IMRX)

$5.19 +0.14 (2.77%)
Market Cap 335.78M
Revenue (ttm) 0.00
Net Income (ttm) -56.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,162,400
Avg Vol 1,678,530
Day's Range N/A - N/A
Shares Out 64.70M
Stochastic %K 93%
Beta 0.41
Analysts Strong Sell
Price Target $16.40

Company Profile

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inh...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8080
Address:
245 Main Street, Second Floor, Cambridge, United States
JuggernautRaider
JuggernautRaider Jul. 4 at 3:25 PM
I agree wholeheartedly @DeepBlueCyan I met a fibromyalgia patient last night who I told how to get free Tonmya. She is a doctor of some sort here in New Jersey. 🇺🇸 She is also a cancer survivor and a tough cookie. 🍪 ask @PeteyUSA or @Proposition_Joe newbie 😋 So I say buy $TNXP . Fibromyalgia patients are waiting all over Hold $SLS - somebody may buy it or it may crash 🤷‍♂️ Buy $ALT - AUD data will be great And buy $IMRX to fight pancreatic cancer - perhaps the deadliest aside from metastatic small cell lung cancer. But Amgen and other companies are already crushing that space with a little DLL3 bispecific called Imdelltra. Google it if you want What business are you in DBC? I am in the Education business. And your price just went up to $84.99 my friend 😜
0 · Reply
hrheasy
hrheasy Jul. 3 at 8:41 PM
$IMRX @TAG01 the CCXI avacopan drug will be discontinued due to ineffectiveness and clinical trial malpractice under fda investigation. https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 3 at 4:20 PM
$ALT $CCCC $IMRX $TLSA all day every day 🏀 💎 💎 💎 💎 👊
0 · Reply
mangingriskandcandles
mangingriskandcandles Jul. 3 at 3:49 AM
$IMRX
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 7:04 PM
$GERN a nice long hem/onc hold like $CCCC or $ALLR or $IMRX
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 5:04 PM
$SLS sold all my shares. $IMRX $TNXP $ALT let’s roll 👊
2 · Reply
_JAKE
_JAKE Jul. 2 at 3:48 PM
$IMRX
0 · Reply
Dognat
Dognat Jul. 1 at 4:11 PM
$IMRX All eyes on RVMD tomorrow. See what they say during their oral presentation for Zoldonrasib + chemotherapy in first-line KRAS G12D metastatic PDAC
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 1 at 1:30 PM
$GE $GERN $HRTX $IMRX all undervalued. Which of these stocks is least like the others ❔ 🤔 🇺🇸
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 30 at 12:35 PM
$URGN may get bought but the NIMBC space is getting competitive and they are expensive. $SNDX … should have been bought $ARDX and the others are new. I’ll check those out. How about $IMRX ? They’re my favorite pancreatic cancer biotech now that Revolution Medicines is way overvalued 😆 🏦
0 · Reply
Latest News on IMRX
Immuneering appoints Andrew Gengos as CFO

2026-06-15T11:43:43.000Z - 19 days ago

Immuneering appoints Andrew Gengos as CFO

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Jun 15, 2026, 7:30 AM EDT - 19 days ago

Immuneering Appoints Andrew Gengos as Chief Financial Officer

Immuneering Transcript: AGM 2026

Jun 11, 2026, 11:00 AM EDT - 23 days ago

Immuneering Transcript: AGM 2026

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Jun 11, 2026, 7:30 AM EDT - 23 days ago

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer

Immuneering announces updated clinical data from atebimetinib combination trial

2026-06-01T13:26:29.000Z - 4 weeks ago

Immuneering announces updated clinical data from atebimetinib combination trial

Immuneering Transcript: Study result

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Immuneering Transcript: Study result

Immuneering Press release: Study result

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Immuneering Press release: Study result

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Jun 1, 2026, 7:30 AM EDT - 4 weeks ago

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

May 21, 2026, 5:00 PM EDT - 6 weeks ago

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Immuneering reports Q1 EPS (21c), consensus (25c)

2026-05-15T14:03:04.000Z - 7 weeks ago

Immuneering reports Q1 EPS (21c), consensus (25c)

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026, 7:35 AM EDT - 7 weeks ago

Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates

Immuneering Earnings release: Q1 2026

May 15, 2026, 7:30 AM EDT - 7 weeks ago

Immuneering Earnings release: Q1 2026

Immuneering Quarterly report: Q1 2026

May 15, 2026, 7:30 AM EDT - 7 weeks ago

Immuneering Quarterly report: Q1 2026

Immuneering announces updated data from Phase 2a trial for atebimetinib

2026-04-21T21:01:42.000Z - 2 months ago

Immuneering announces updated data from Phase 2a trial for atebimetinib

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Apr 21, 2026, 4:05 PM EDT - 2 months ago

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

Immuneering announces presentation of new genetic data at 2026 AACR

2026-04-20T14:04:20.000Z - 2 months ago

Immuneering announces presentation of new genetic data at 2026 AACR

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Apr 20, 2026, 9:00 AM EDT - 2 months ago

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Immuneering Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Immuneering Proxy statement: Proxy filing

Immuneering Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 2 months ago

Immuneering Proxy statement: Proxy filing

Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 3:45 PM EDT - 2 months ago

Immuneering Transcript: 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 4:05 PM EDT - 3 months ago

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Mar 17, 2026, 4:35 PM EDT - 3 months ago

Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival

Immuneering Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:40 PM EDT - 4 months ago

Immuneering Transcript: Leerink Global Healthcare Conference 2026

Immuneering price target lowered to $12 from $13 at Piper Sandler

2026-03-09T10:56:34.000Z - 4 months ago

Immuneering price target lowered to $12 from $13 at Piper Sandler

Immuneering Annual report: Q4 2025

Mar 6, 2026, 8:00 AM EST - 4 months ago

Immuneering Annual report: Q4 2025

Immuneering Earnings release: Q4 2025

Mar 6, 2026, 8:00 AM EST - 4 months ago

Immuneering Earnings release: Q4 2025

Immuneering reports Q4 EPS (18), consensus (31c)

2026-03-06T12:52:29.000Z - 4 months ago

Immuneering reports Q4 EPS (18), consensus (31c)

Immuneering sees cash runway into 2029

2026-03-06T12:52:10.000Z - 4 months ago

Immuneering sees cash runway into 2029

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 6, 2026, 7:45 AM EST - 4 months ago

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering to Present at the Leerink Global Healthcare Conference

Mar 2, 2026, 4:05 PM EST - 4 months ago

Immuneering to Present at the Leerink Global Healthcare Conference

Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 10:00 AM EST - 4 months ago

Immuneering Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 4:05 PM EST - 4 months ago

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

2026-01-08T17:55:15.000Z - 6 months ago

Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink

RVMD

Immuneering reports ‘positive’ survival, safety data from atebimetinib trial

2026-01-07T23:45:14.000Z - 6 months ago

Immuneering reports ‘positive’ survival, safety data from atebimetinib trial

Immuneering Transcript: Study Result

Jan 7, 2026, 4:30 PM EST - 6 months ago

Immuneering Transcript: Study Result

Immuneering Press release: Study Result

Jan 7, 2026, 4:30 PM EST - 6 months ago

Immuneering Press release: Study Result

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Jan 7, 2026, 4:00 PM EST - 6 months ago

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering management to meet with Oppenheimer

2026-01-07T19:25:26.000Z - 6 months ago

Immuneering management to meet with Oppenheimer

Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP

2025-12-23T13:11:36.000Z - 6 months ago

Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Dec 23, 2025, 8:00 AM EST - 6 months ago

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering on track to dose first patient in pancreatic cancer trial in 2026

2025-12-17T21:20:40.000Z - 7 months ago

Immuneering on track to dose first patient in pancreatic cancer trial in 2026

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Dec 17, 2025, 4:05 PM EST - 7 months ago

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 16, 2025, 8:00 AM EST - 7 months ago

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 11:10 AM EST - 7 months ago

Immuneering Transcript: Piper Sandler 37th Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 7 months ago

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Immuneering Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Immuneering Earnings Call Transcript: Q3 2025

Immuneering Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Immuneering Quarterly report: Q3 2025

Immuneering Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 8 months ago

Immuneering Earnings release: Q3 2025

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Nov 12, 2025, 4:05 PM EST - 8 months ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Nov 4, 2025, 4:05 PM EST - 8 months ago

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Sep 26, 2025, 4:01 PM EDT - 10 months ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Sep 25, 2025, 12:08 AM EDT - 10 months ago

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Sep 24, 2025, 4:05 PM EDT - 10 months ago

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Sep 24, 2025, 4:01 PM EDT - 10 months ago

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Sep 16, 2025, 7:00 AM EDT - 10 months ago

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Sep 10, 2025, 7:00 AM EDT - 10 months ago

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

Immuneering Registration statement: Registration Filing

Sep 3, 2025, 8:00 AM EDT - 10 months ago

Immuneering Registration statement: Registration Filing

Immuneering Announces Closing of $25 Million Private Placement

Aug 26, 2025, 4:05 PM EDT - 11 months ago

Immuneering Announces Closing of $25 Million Private Placement

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Aug 25, 2025, 8:00 AM EDT - 11 months ago

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

LLY

Immuneering Announces $25 Million Private Placement

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Immuneering Announces $25 Million Private Placement

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 4:05 PM EDT - 11 months ago

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Immuneering Registration statement: Registration Filing

Aug 13, 2025, 8:00 AM EDT - 11 months ago

Immuneering Registration statement: Registration Filing

Immuneering Quarterly report: Q2 2025

Aug 13, 2025, 12:00 AM EDT - 11 months ago

Immuneering Quarterly report: Q2 2025

Immuneering Earnings release: Q2 2025

Aug 13, 2025, 12:00 AM EDT - 11 months ago

Immuneering Earnings release: Q2 2025

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib

Immuneering Transcript: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Transcript: Study Update

Immuneering Press release: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Press release: Study Update

Immuneering Slides: Study Update

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Immuneering Slides: Study Update

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Jun 17, 2025, 6:00 AM EDT - 1 year ago

Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Immuneering Transcript: Jefferies Global Healthcare Conference 2025

Immuneering to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

May 5, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates

Immuneering Quarterly report: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Quarterly report: Q1 2025

Immuneering Earnings release: Q1 2025

May 5, 2025, 12:00 AM EDT - 1 year ago

Immuneering Earnings release: Q1 2025

Immuneering Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Immuneering Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immuneering Proxy statement: Proxy Filing

Immuneering Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 9, 2025, 1:30 PM EDT - 1 year ago

Immuneering Transcript: 24th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference

Immuneering Corporation Announces Grant of Inducement Award

Mar 21, 2025, 4:30 PM EDT - 1 year ago

Immuneering Corporation Announces Grant of Inducement Award

Immuneering Annual report: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Annual report: Q4 2024

Immuneering Earnings release: Q4 2024

Mar 20, 2025, 5:00 PM EDT - 1 year ago

Immuneering Earnings release: Q4 2024

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 4:05 PM EDT - 1 year ago

Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Immuneering Names Dr. Igor Matushansky as Chief Medical Officer

Immuneering Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 2:40 PM EST - 1 year ago

Immuneering Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Immuneering Transcript: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Transcript: Study Result

Immuneering Press release: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Press release: Study Result

Immuneering Slides: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

Immuneering Slides: Study Result

Immuneering Launches Pancreatic Cancer Advisory Board

Dec 19, 2024, 8:00 AM EST - 1 year ago

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Dec 12, 2024, 8:00 AM EST - 1 year ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma

Immuneering Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 5, 2024, 1:00 PM EST - 1 year ago

Immuneering Transcript: Piper Sandler 36th Annual Healthcare Conference

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

Immuneering Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Quarterly report: Q3 2024

Immuneering Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Immuneering Earnings release: Q3 2024

Immuneering Transcript: Study Update

Sep 12, 2024, 4:30 PM EDT - 1 year ago

Immuneering Transcript: Study Update

Immuneering Press release: Study Update

Sep 12, 2024, 4:30 PM EDT - 1 year ago

Immuneering Press release: Study Update

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Sep 12, 2024, 4:05 PM EDT - 1 year ago

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Immuneering Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 10:00 AM EDT - 1 year ago

Immuneering Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 6, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Quarterly report: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immuneering Quarterly report: Q2 2024

Immuneering Earnings release: Q2 2024

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immuneering Earnings release: Q2 2024

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Jul 31, 2024, 4:05 PM EDT - 2 years ago

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering Transcript: Jefferies 2024 Global Healthcare Conference

Jun 5, 2024, 4:30 PM EDT - 2 years ago

Immuneering Transcript: Jefferies 2024 Global Healthcare Conference

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

May 7, 2024, 4:05 PM EDT - 2 years ago

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Immuneering Quarterly report: Q1 2024

Immuneering Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Immuneering Earnings release: Q1 2024

Immuneering Recognizes Melanoma Awareness Month

May 6, 2024, 4:30 PM EDT - 2 years ago

Immuneering Recognizes Melanoma Awareness Month

Immuneering Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Immuneering Proxy statement: Proxy Filing

Immuneering Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Immuneering Proxy statement: Proxy Filing

Immuneering Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 11, 2024, 3:00 PM EDT - 2 years ago

Immuneering Transcript: 23rd Annual Needham Virtual Healthcare Conference

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Apr 9, 2024, 12:00 PM EDT - 2 years ago

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 4:05 PM EDT - 2 years ago

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

JuggernautRaider
JuggernautRaider Jul. 4 at 3:25 PM
I agree wholeheartedly @DeepBlueCyan I met a fibromyalgia patient last night who I told how to get free Tonmya. She is a doctor of some sort here in New Jersey. 🇺🇸 She is also a cancer survivor and a tough cookie. 🍪 ask @PeteyUSA or @Proposition_Joe newbie 😋 So I say buy $TNXP . Fibromyalgia patients are waiting all over Hold $SLS - somebody may buy it or it may crash 🤷‍♂️ Buy $ALT - AUD data will be great And buy $IMRX to fight pancreatic cancer - perhaps the deadliest aside from metastatic small cell lung cancer. But Amgen and other companies are already crushing that space with a little DLL3 bispecific called Imdelltra. Google it if you want What business are you in DBC? I am in the Education business. And your price just went up to $84.99 my friend 😜
0 · Reply
hrheasy
hrheasy Jul. 3 at 8:41 PM
$IMRX @TAG01 the CCXI avacopan drug will be discontinued due to ineffectiveness and clinical trial malpractice under fda investigation. https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 3 at 4:20 PM
$ALT $CCCC $IMRX $TLSA all day every day 🏀 💎 💎 💎 💎 👊
0 · Reply
mangingriskandcandles
mangingriskandcandles Jul. 3 at 3:49 AM
$IMRX
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 7:04 PM
$GERN a nice long hem/onc hold like $CCCC or $ALLR or $IMRX
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 2 at 5:04 PM
$SLS sold all my shares. $IMRX $TNXP $ALT let’s roll 👊
2 · Reply
_JAKE
_JAKE Jul. 2 at 3:48 PM
$IMRX
0 · Reply
Dognat
Dognat Jul. 1 at 4:11 PM
$IMRX All eyes on RVMD tomorrow. See what they say during their oral presentation for Zoldonrasib + chemotherapy in first-line KRAS G12D metastatic PDAC
0 · Reply
JuggernautRaider
JuggernautRaider Jul. 1 at 1:30 PM
$GE $GERN $HRTX $IMRX all undervalued. Which of these stocks is least like the others ❔ 🤔 🇺🇸
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 30 at 12:35 PM
$URGN may get bought but the NIMBC space is getting competitive and they are expensive. $SNDX … should have been bought $ARDX and the others are new. I’ll check those out. How about $IMRX ? They’re my favorite pancreatic cancer biotech now that Revolution Medicines is way overvalued 😆 🏦
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 11:40 PM
$IMRX i am investing some of my 10x wins from $SLS here, in $ALT , and also $TNXP
0 · Reply
D541
D541 Jun. 29 at 7:54 PM
$IMRX here with 25% short interest we are getting spicy
0 · Reply
D541
D541 Jun. 29 at 7:53 PM
$IMRX
0 · Reply
Bigbucksnow
Bigbucksnow Jun. 29 at 4:59 PM
$IMRX
0 · Reply
AlwaysBullish99
AlwaysBullish99 Jun. 29 at 4:05 PM
$IMRX The 5 day chart with higher highs and lower lows looks great. Completion of Phase III patient enrollment and Lung Cancer Phase II clinical trials on the way. The pipeline is looking great.
0 · Reply
AlwaysBullish99
AlwaysBullish99 Jun. 29 at 1:53 PM
$IMRX This trend needs to break $5.
0 · Reply
watchaddict
watchaddict Jun. 29 at 1:45 PM
$IMRX adding LFG
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 29 at 3:00 AM
$SLS alright I have 8x’ed on SELLAS from my initial position at $1.50 a share and I do not get why the CEO Stergiou just received another 1 million shares just for doing his job. I may begin Selling shares to buy others like $CGTX $CCCC and $IMRX amongst others. Thoughts? I have no problem locking in some incredible long term capital gains. AML is incredibly deadly but rare. Perhaps SELLAS will be bought but by whom?
4 · Reply
OptimistJP
OptimistJP Jun. 28 at 9:08 PM
$IMRX Basic Stats Short Interest Statistics Short Interest 12,724,428 Shares - source: NASDAQ Short Interest Ratio 11.13 Days to Cover Short Interest % Float 25.74 % - source: NASDAQ (Short Interest), Capital IQ (float) Short Volume Statistics Off-Exchange Short Volume 207,347 Shares - source: FINRA (inc. Dark Pool volume) Off-Exchange Short Volume Ratio 44.44 % - source: FINRA (inc. Dark Pool volume)
0 · Reply
OptimistJP
OptimistJP Jun. 28 at 8:44 PM
$IMRX Institutional Ownership and Shareholders Immuneering Corporation (US:IMRX) has 102 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 32,031,538 shares. Largest shareholders include Fmr Llc, Sanofi, Vanguard Group Inc, Vanguard Capital Management Llc, Marshall Wace, Llp, Price T Rowe Associates Inc /md/, BlackRock, Inc., Millennium Management Llc, Geode Capital Management, Llc, and Occam Crest Management LP .
0 · Reply
AlwaysBullish99
AlwaysBullish99 Jun. 26 at 9:49 PM
$IMRX Today was the Russell 3000 reconstruction and IMRX was added to the index since being removed back in 2024.
1 · Reply
rekc
rekc Jun. 26 at 8:47 PM
$IMRX It was probably the unwind of an artificially shorted position from earlier. Shorted from one account and bought in another related one. I assume there is not much significance to the volume.
1 · Reply